Back to top
more

Veracyte (VCYT)

(Delayed Data from NSDQ)

$23.76 USD

23.76
699,470

+0.34 (1.45%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $23.76 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Globus Medical (GMED) Global Sales, Innovation Aid Growth

by Zacks Equity Research

In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.

Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D

by Zacks Equity Research

Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.

Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar?

by Zacks Equity Research

Veracyte (VCYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: NVIDIA, Twist Bioscience, Ollie's Bargain Outlet in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

AxoGen (AXGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Urmimala Biswas headshot

3 Medical Instruments Picks to Navigate Industry Challenges

by Urmimala Biswas

Deteriorating geopolitical situation and supply bottlenecks mar the prospects of the Zacks Medical Instruments industry. Yet, HOLX, MASI and VCYT are worth buying based on strategic developments and fundamentals.

Zacks.com featured highlights Veracyte, Steelcase and Applied Industrial

by Zacks Equity Research

Veracyte, Steelcase and Applied Industrial have been highlighted in this Screen of The Week article.

Santanu Roy headshot

3 Top-Ranked Efficient Stocks to Increase Your Portfolio Returns

by Santanu Roy

Invest in companies like Veracyte (VCYT), Steelcase (SCS) and Applied Industrial Technologies (AIT), as they boast higher efficiency levels.

Wall Street Analysts See a 37.09% Upside in Veracyte (VCYT): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Veracyte (VCYT) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How to Find Strong Buy Medical Stocks Using the Zacks Rank

by Zacks Equity Research

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.07%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 39.1% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Veracyte (VCYT) Crossed Above the 50-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

Zacks.com featured highlights include Veracyte, Signet Jewelers, UMB Financial and NVIDIA

by Zacks Equity Research

Veracyte, Signet Jewelers, UMB Financial and NVIDIA are part of the Zacks Screen of the Week article.

Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners

by Zacks Equity Research

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Santanu Roy headshot

4 Must-Buy Efficient Stocks to Enrich Your Portfolio

by Santanu Roy

Invest in companies like Veracyte (VCYT), Signet Jewelers (SIG), UMB Financial (UMBF) and NVIDIA (NVDA) to make the most of higher efficiency levels.

Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care

by Zacks Equity Research

Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.

Nalak Das headshot

Buy 5 Medical Instruments Stocks to Enhance Your Portfolio

by Nalak Das

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.

Veracyte (VCYT) Up 6% Since Last Earnings: Will it Continue?

by Zacks Equity Research

Investors are optimistic about Veracyte (VCYT) led by strength in the testing business and upbeat guidance.

Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Veracyte (VCYT) points to a 39.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Moumi Mondal headshot

Here's How Medtronic (MDT) Is Placed Ahead of Q4 Earnings

by Moumi Mondal

Medtronic's (MDT) rapid cadence of new product approvals is a strong foundation for future growth. However, the company also navigates some macroeconomic challenges.

Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View

by Zacks Equity Research

Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.

Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 54.55% and 3.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands

by Zacks Equity Research

Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.